CMIC HOLDINGS Past Earnings Performance
Past criteria checks 1/6
CMIC HOLDINGS has been growing earnings at an average annual rate of 39.5%, while the Life Sciences industry saw earnings growing at 31.7% annually. Revenues have been growing at an average rate of 10.3% per year. CMIC HOLDINGS's return on equity is 15.2%, and it has net margins of 5.7%.
Key information
39.5%
Earnings growth rate
40.8%
EPS growth rate
| Life Sciences Industry Growth | 32.0% |
| Revenue growth rate | 10.3% |
| Return on equity | 15.2% |
| Net Margin | 5.7% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How CMIC HOLDINGS makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 93,111 | 5,327 | 13,867 | 0 |
| 30 Sep 23 | 104,701 | 7,152 | 14,434 | 0 |
| 30 Jun 23 | 115,910 | 10,091 | 14,977 | 0 |
| 31 Mar 23 | 116,575 | 11,429 | 15,160 | 0 |
| 31 Dec 22 | 113,509 | 8,230 | 14,980 | 0 |
| 30 Sep 22 | 108,461 | 8,387 | 14,412 | 0 |
| 30 Jun 22 | 105,009 | 6,012 | 13,914 | 0 |
| 31 Mar 22 | 98,912 | 4,304 | 13,431 | 0 |
| 31 Dec 21 | 91,532 | 3,569 | 12,946 | 0 |
| 30 Sep 21 | 85,788 | 2,023 | 12,806 | 0 |
| 30 Jun 21 | 78,508 | 1,075 | 12,326 | 0 |
| 31 Mar 21 | 75,785 | 1,248 | 12,016 | 0 |
| 31 Dec 20 | 75,183 | 1,585 | 11,908 | 0 |
| 30 Sep 20 | 76,098 | 1,505 | 12,041 | 0 |
| 30 Jun 20 | 76,254 | 2,286 | 12,117 | 0 |
| 31 Mar 20 | 76,698 | 1,765 | 12,398 | 0 |
| 31 Dec 19 | 76,774 | 1,767 | 12,103 | 0 |
| 30 Sep 19 | 74,373 | 1,822 | 11,706 | 0 |
| 30 Jun 19 | 73,100 | 2,167 | 11,376 | 0 |
| 31 Mar 19 | 72,862 | 2,534 | 11,032 | 0 |
| 31 Dec 18 | 70,631 | 1,479 | 10,768 | 0 |
| 30 Sep 18 | 69,869 | 1,487 | 10,570 | 0 |
| 30 Jun 18 | 68,928 | 1,754 | 10,375 | 0 |
| 31 Mar 18 | 67,179 | 1,506 | 10,366 | 0 |
| 31 Dec 17 | 66,530 | 1,894 | 10,431 | 0 |
| 30 Sep 17 | 65,282 | 1,550 | 10,340 | 0 |
| 30 Jun 17 | 63,781 | 1,037 | 10,082 | 0 |
| 31 Mar 17 | 63,015 | 582 | 9,938 | 0 |
| 31 Dec 16 | 62,795 | 874 | 9,751 | 0 |
| 30 Sep 16 | 62,039 | 878 | 9,733 | 0 |
| 30 Jun 16 | 61,332 | 749 | 9,866 | 0 |
| 31 Mar 16 | 60,160 | 174 | 10,019 | 0 |
| 31 Dec 15 | 57,474 | -569 | 9,787 | 0 |
| 30 Sep 15 | 55,904 | -542 | 9,676 | 0 |
| 30 Jun 15 | 54,839 | -468 | 9,290 | 0 |
| 31 Mar 15 | 53,841 | 542 | 8,724 | 0 |
| 31 Dec 14 | 52,801 | 1,034 | 8,504 | 0 |
| 30 Sep 14 | 52,836 | 1,174 | 8,120 | 0 |
| 30 Jun 14 | 51,904 | 1,567 | 7,992 | 0 |
| 31 Mar 14 | 51,231 | 1,165 | 8,039 | 0 |
| 31 Dec 13 | 51,176 | 1,450 | 8,007 | 0 |
| 30 Sep 13 | 50,934 | 1,753 | 7,985 | 0 |
| 30 Jun 13 | 50,889 | 1,724 | 7,936 | 0 |
Quality Earnings: 2309 has a large one-off gain of ¥1.9B impacting its last 12 months of financial results to 31st December, 2023.
Growing Profit Margin: 2309's current net profit margins (5.7%) are lower than last year (7.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 2309's earnings have grown significantly by 39.5% per year over the past 5 years.
Accelerating Growth: 2309's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 2309 had negative earnings growth (-35.3%) over the past year, making it difficult to compare to the Life Sciences industry average (-20.2%).
Return on Equity
High ROE: 2309's Return on Equity (15.2%) is considered low.